Therefore, these data suggest that IL4R inhibition might be a therapeutic avenue to inhibit Th2 suppression of the cytotoxic immune response and enhance immunotherapy for deadly bone and lung metastatic disease. This evidence concerns the gene IL4R and medical procedure.